Genertec Universal Medical boosts 2026 procurement cap with GT-PRC to RMB 680.00 million

Bulletin Express04-27 18:05

Genertec Universal Medical Group Company Limited (stock name: UNI MEDICAL) has approved a 33.3% increase in its 2026 annual limit for purchasing medical products, equipment, and associated logistics services from controlling shareholder China General Technology (Group) Holding Co. Ltd. (GT-PRC) and its affiliates.

Revised cap • New 2026 cap: RMB 680.00 million • Original 2026 cap: RMB 510.00 million

Utilisation to date • 2024 cap: RMB 266.00 million; actual spend: RMB 249.29 million • 2025 cap: RMB 547.83 million; actual spend: RMB 547.83 million

Rationale Management cited accelerating demand from the company’s expanding hospital network and stronger internal supply-chain synergies following GT-PRC’s “synergistic development of China National Medicines and Chongqing Pharmaceutical Holdings” strategy and its equity investment in Neusoft Medical. For 2026 the group expects RMB 610.00 million of drug and consumables procurement and RMB 70.00 million of equipment purchases, lifting total demand to around RMB 680.00 million.

Regulatory framework GT-PRC owns 37.66% of UNI MEDICAL, making the transactions continuing connected transactions under Chapter 14A of the Hong Kong Listing Rules. As the revised cap exceeds the 5% materiality threshold, the proposal is subject to disclosure, annual review, and independent shareholders’ approval. GT-PRC and its associates will abstain from voting at the forthcoming annual general meeting; a circular is slated for release by 19 May 2026.

Pricing & controls The 2024 Medical Related Product Procurement Framework Agreement (effective 1 January 2024 to 31 December 2026) remains unchanged. Prices are set by: 1. Government-mandated rates where applicable; 2. Comparable market prices; or 3. Cost-plus mark-ups aligned with industry gross margins.

To safeguard minority interests, the company maintains layered internal controls, including market-price benchmarking, multi-party quotation reviews, monthly cap monitoring, annual audits, and oversight by an Independent Board Committee. Gram Capital Limited has been appointed independent financial adviser for the shareholder vote.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment